Bausch Health Companies Inc. BHC revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Bausch Health Companies Inc. reported revenue across 3 products and services; the largest, Product, was $10.2B, 98.8% of the filed sum (+6.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Product$10.2B98.8%+6.7% yoy
- Product And Service Other$110M1.1%+2.8% yoy
- Price Appreciation Credit$18M0.2%0.0% yoy
Members sum to the consolidated $10.3B for this period.
- United Statesand Puerto Rico$6.14B59.8%+6.4% yoy
- Other countries$1.15B11.2%+6.5% yoy
- China$493M4.8%-0.6% yoy
- Canada$417M4.1%+3.7% yoy
- PL$382M3.7%+9.1% yoy
- Mexico$278M2.7%-11.7% yoy
- France$249M2.4%+8.3% yoy
- South Korea$234M2.3%+60.3% yoy
- +6 more members in the filing
Members sum to the consolidated $10.3B for this period.
- Product$2.83B99.1%+12.8% yoy
- Product And Service Other$27M0.9%+3.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.